{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-230611","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2023-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.287670+00:00","generated_at":"2026-06-10T22:57:06.992729+00:00","sec_items":["3.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aligos receives Nasdaq delisting notice for bid price below $1.00","bullets":["Notice on Sep 5, 2023: stock failed to maintain $1.00 minimum bid for 30 consecutive business days through Sep 1.","Company has 180 calendar days, until Mar 4, 2024, to regain compliance by closing at $1.00 for 10 consecutive days.","If not cured, Aligos may be eligible for an additional 180-day period by transferring to Nasdaq Capital Market.","Company intends to monitor bid price and consider options, but compliance is not assured.","Potential delisting could occur if Staff determines cure is unlikely or other standards unmet."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-230611","json":"https://secwatch.observer/filing/0001193125-23-230611.json","markdown":"https://secwatch.observer/filing/0001193125-23-230611.md","text":"https://secwatch.observer/filing/0001193125-23-230611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000119312523230611/0001193125-23-230611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000119312523230611/d549184d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:57:06.992729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a1c89884a118804d3d7f2151a95cb13849ee1f0c","claim":"Aligos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"rough September 1, 2023, the Company’s common stock, $0.0001 par value per share (the “Common Stock”), had not maintained a minimum bid price of $1.00 per share, required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). Nasdaq’s written notice does not result in the immediate delisting of the Common Stock from the Nasdaq Global Market In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has 180 calendar days, or until March 4, 2024 (the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement.","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000119312523230611/0001193125-23-230611-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}